Patients & Families

Grid is committed to advancing our unique strategy to develop better and safer medicines for our patients. This has and will continue to be our sole mission.

Phase 1b study in patients with refractory, advanced stage (III/IV) and recurrent Non-Small Cell Lung Cancer (NSCLC)

Our Phase Ib expansion cohort for patients with NSCLC is currently enrolling at the following clinical sites:

• Duke Cancer Institute (Durham, NC)
  (919) 681-4768
• Advent Health (Celebration, FL)
  (407) 303-4000
• Karmanos Cancer Institute (Detroit, MI)
  1-800-527-6266
• Additional information on the Phase 1b study can be found on Clinicaltrials.gov.

Phase 2 study in patients with relapsed or refractory metastatic NSCLC

Our Phase 2 GT103 combination trial with Pembrolizumab (Keytruda®) has also been initiated at the sites listed below. Additional clinical trial sites are expected to open soon.

• Duke Cancer Institute (Durham, NC)
  (919) 681-4768
• Karmanos Cancer Institute (Detroit, MI)
  1-800-527-6266
• University of Virginia Cancer Center (Charlottesville, VA)
  (434) 310-0587
• Summit Health (Florham Park, NJ)
  (908) 273-4300
• University of Illinois – Chicago (Chicago, IL)
  (312) 355-5112
• Additional information on the Phase 2 study can be found on Clinicaltrials.gov.

For further support or questions contact:
Grid Therapeutics
Dr. Edward Patz
edward.patz@gridthr.com
Duke Thoracic Oncology
Phone number (919) 681-4768